# cellspect

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cellspect

- Industry: Pharmaceuticals
- Headquarters: Morioka-shi, Japan
- Website: www.cellspect.com/
- Total disclosed funding: $1.3M
- Latest round: Series A (Apr 1, 2016)
- Investors on record: 2

## About

Based in Japan, Cellspect Co., Ltd. operates in the healthcare sector, specializing in diagnostic products and research tools that enhance clinical testing and scientific research.Cellspect Co., Ltd. is a company focused on developing diagnostic technologies and research tools. Founded in 2014 in Morioka-shi, Japan, it has completed 8 deals to date. The latest funding round was a VENTURE DEBT round on May 16, 2025, where the company raised JPY 1,200.000 mn from the Development Bank of Japan, bringing the total amount raised to JPY 400.000 mn.Cellspect Co., Ltd. specializes in a diverse array of diagnostic products and research tools aimed at enhancing healthcare and scientific research. The company's primary offerings include the Quonpass® COVID-19 Antigen Testing Kits, available in both professional and home-use formats, as well as the Compass View MD3 clinical testing services tailored for healthcare institutions. Their research products, such as Metal Assays, Micro Assays, and Redox Assays, serve laboratories and research facilities, addressing critical needs in microbial analysis and antimicrobial resistance studies. These products are designed for a broad customer base, including hospitals, research institutions, and public health organizations, particularly within Japan and select international markets. The company is also active in open innovation initiatives and social contributions, indicating a strong commitment to advancing healthcare solutions through collaborative research efforts.Cellspect Co., Ltd. generates revenue through a combination of direct-to-consumer sales and business-to-business transactions. The primary revenue streams stem from the sale of their diagnostic kits and clinical testing services, with potential partnerships established with healthcare providers and research institutions. The flagship product, Quonpass® COVID-19 Antigen Testing Kit, represents a significant portion of their revenue, catering to both individual consumers and healthcare facilities. Typical transactions involve direct purchases by clients, who may place orders for bulk quantities of diagnostic kits or subscribe to ongoing clinical testing services. The company’s commitment to quality and innovation in their product offerings has positioned them as a key provider within the healthcare diagnostics market.In May 2025, Cellspect raised an undisclosed amount in venture funding from a new investor, MIRAIDOOR. The funding will be utilized to improve the accuracy of cancer treatment. The company is focused on introducing new diagnostic products in the near future and aims to expand its market presence in additional international regions by the end of 2025.

## Funding rounds

- Series A, Apr 1, 2016, $1.3M — Mizuho Capital, Iwagin Jigyo Souzou Capital

## Investors

- Mizuho Capital (https://capitalatlas.ai/funds/mizuho-capital) — Series A
- Iwagin Jigyo Souzou Capital (https://capitalatlas.ai/funds/iwagin-jigyo-souzou-capital) — Series A